Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 8/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18321651 | 0.88 | FASN (0.51) | FASNMTORUSP7PIK3CA | |
| SCHEMBL31696891 | 0.86 | ALDH1A1 (0.46) | FASNALDH1A1 | |
| SCHEMBL18333437 | 0.86 | ALDH1A1 (0.46) | FASNALDH1A1 | |
| SCHEMBL18321509 | 0.86 | ALDH1A1 (0.46) | FASNALDH1A1 | |
| SCHEMBL18321366 | 0.86 | ALDH1A1 (0.46) | FASNALDH1A1 | |
| SCHEMBL18321766 | 0.83 | FASN (0.53) | FASN | |
| SCHEMBL31696899 | 0.83 | FASN (0.53) | FASN | |
| Trifluoroacetic Acid SCHEMBL18321565 | 0.83 | MTOR (0.47) | FASNMTORPIK3CA | |
| SCHEMBL18321742 | 0.81 | FASN (0.59) | FASNALDH1A1FAAH | |
| SCHEMBL22738312 | 0.80 | FASN (0.42) | FASNFAAHCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | claimed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | claimed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | claimed |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2022-03-17 | — | — | US | claimed |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | 89BIO LTD (IL) | 2021-02-16 | — | — | US | claimed |
| EP-3310773-B1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-12-02 | — | — | EP | claimed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | claimed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | claimed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | claimed |
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | CEPHALON LLC (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2024-05-23 | — | — | US | disclosed |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | 89BIO LTD (IL) | 2024-01-23 | — | — | US | disclosed |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | CEPHALON LLC | 2022-03-17 | — | — | US | disclosed |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | 89BIO LTD (IL) | 2021-02-16 | — | — | US | disclosed |
| EP-3310773-B1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | 89BIO LTD (IL) | 2020-12-02 | — | — | EP | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON LLC | 2020-01-30 | — | — | US | disclosed |
| EP-3310773-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | Cephalon, Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016205590-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | CEPHALON, INC. (US) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441702-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | FASN 1/4885MTOR 1971/4885USP7 2682/4885 |
| US-20240166625-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | FASN 1/4885MTOR 1971/4885USP7 2682/4885 |
| US-20200031797-A1 | SUBSTITUTED 4-BENZYL AND 4-BENZOYL PIPERIDINE DERIVATIVES | FASN, FADS1, ASS1 | FASN 1/4885MTOR 1842/4885USP7 3906/4885 |
| US-10919875-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivatives | FASN, CES1, FADS2 | FASN 1/4885MTOR 1955/4885USP7 2736/4885 |
| US-20220081411-A1 | Substituted 4-Benzyl And 4-Benzoyl Piperidine Derivates | FASN, CES1, FADS2 | FASN 1/4885MTOR 1971/4885USP7 2682/4885 |
| US-11878966-B2 | Substituted 4-benzyl and 4-benzoyl piperidine derivates | FASN, CES1, FADS2 | FASN 1/4885MTOR 1971/4885USP7 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.